ID

24890

Descripción

Study ID: 101468/166 Clinical Study ID: SKF-101468/166 Study Title: A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Parkinson Disease

Palabras clave

Versiones (3)
  1. 22/8/17 22/8/17 -
  2. 22/8/17 22/8/17 -
  3. 4/9/17 4/9/17 -
Titular de derechos de autor

GlaxoSmithKline

Subido en

22 de agosto de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

randomization determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166

Inglés

randomization determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166

1 formularios  
RANDOMIZATION AND COHORT ASSIGNMENT
Descripción

RANDOMIZATION AND COHORT ASSIGNMENT

Alias
UMLS CUI-1
C0034656
After review of all eligibility criteria is the patient eligible for the study?
Descripción

patient eligible for clinical trial

Tipo de datos

text

Alias
UMLS CUI [1]
C1302261
Randomization Number
Descripción

randomization numb

Tipo de datos

integer

Alias
UMLS CUI [1]
C2986235
Volver a la parte superior de la página

Similar models

randomization determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
RANDOMIZATION AND COHORT ASSIGNMENT
C0034656 (UMLS CUI-1)
Item
After review of all eligibility criteria is the patient eligible for the study?
text
C1302261 (UMLS CUI [1])
patient eligible for clinical trial
Code List
After review of all eligibility criteria is the patient eligible for the study?
CL Item
Yes - Please telephone the Central Randomization Center to enroll the patient. Record the assigned (1)
CL Item
Randomization Number and check the appropriate box to indicate the assigned Cohort in the (Randomization Number and check the appropriate box to indicate the assigned Cohort in the)
CL Item
section below. (section below.)
CL Item
No - Record the reason for Screen Failure on the "Patient Screening/Enrollment Log." (2)
randomization numb
Item
Randomization Number
integer
C2986235 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial